Molecular docking unveils the potential of andrographolide derivatives against COVID-19: an in silico approach
Tóm tắt
The recent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection cause high mortality and there is an emergency need to develop a specific drug to treat the novel coronavirus disease, COVID-19. However, some natural and synthetic products with action against SARS-CoV-2 have been reported in recent research, there is no specific drug available for treating COVID-19. In the present study, molecular interaction analysis was performed for 16 semisynthetic andrographolides (AGP) against 5 SARS-CoV-2 enzymes main protease (Mpro, PDB: 6LU7), papain-like protease (PLpro, PDB: 6WUU), spike glycoprotein (S, PDB: 6VXX), NSP15 endoribonuclease (NSP15, PDB: 6VWW), and RNA-dependent RNA polymerase (RdRp, PDB: 6M71). Moreover, the compounds pharmacokinetic and toxic profiles were also analyzed using computational tools. The protein−ligand docking score (kcal/mol) revealed that all the tested AGP derivatives showed a better binding affinity towards all the tested enzymes than hydroxychloroquine (HCQ). Meanwhile, all the tested AGP derivatives showed a better binding score with RdRp and S than remdesivir (REM). Interestingly, compounds 12, 14, and 15 showed a better binding affinity towards the all the tested enzyme than AGP, REM, and HCQ. AGP-16 had shown − 8.7 kcal/mol binding/docking score for Mpro, AGP-15 showed − 8.6 kcal/mol for NSP15, and AGP-10, 13, and 15 exhibited − 8.7, − 8.9, and − 8.7 kcal/mol, respectively, for S. Overall results of the present study concluded that AGP derivatives 14 and 15 could be the best ‘lead’ candidate for the treatment against SARS-CoV-2 infection. However, molecular dynamic studies and pharmacological screenings are essential to developing AGP derivatives 14 and 15 as a drug against COVID-19.
Tài liệu tham khảo
WHO Coronavirus disease (COVID-19) dashboard (2020) COVID 19 Special Issue 10.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513
Stadler K, Masignani V, Eickmann M, Becker S, Abrignani S, Klenk HD, Rappuoli R (2003) SARS—beginning to understand a new virus. Nat Rev Microbio 1:209–218
Li F, Li W, Farzan M, Harrison SC (2005) Structure of SARS coronavirus spike receptor−binding domain complexed with receptor. Science 309:1864–1868
Elfiky AA (2020) Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 248:117477
Jayakumar T, Hsieh C-Y, Lee J-J, Sheu J-R (2013) Experimental and clinical pharmacology of Andrographis paniculata and its major bioactive phytoconstituent andrographolide. Evid Based Complement Alternat Med 2013:846740
Wipatayotin A (n.d) Local herb study on Covid-19 patients to continue. Bangkok Post
Wang C, Sun S, Ding X (2021) The therapeutic effects of traditional chinese medicine on COVID-19: a narrative review. Int J Clin Pharm 43:35–45
Shi T-H, Huang Y-L, Chen C-C, Pi W-C, Hsu Y-L, Lo L-C, Chen W-Y, Fu S-L, Lin C-H (2020) Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-nCoV and SARS-CoV through covalent linkage. Biochem Biophys Res Commun 533:467–473
Kanjanasirirat P, Suksatu A, Manopwisedjaroen S, Munyoo B, Tuchinda P, Jearawuttanakul K, Seemakhan S, Charoensutthivarakul S, Wongtrakoongate P, Rangkasenee N, Pitiporn S, Waranuch N, Chabang N, Khemawoot P, Sa-Ngiamsuntorn K, Pewkliang Y, Thongsri P, Chutipongtanate S, Hongeng S, Borwornpinyo S, Thitithanyanont A (2020) High-content screening of Thai medicinal plants reveals Boesenbergia rotunda extract and its component Panduratin A as anti-SARS-CoV-2 agents. Sci Rep 10:19963
Alazmi M, Motwalli O (2020) Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV- 2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates. J Mol Model 26:338
Enmozhi SK, Raja K, Sebastine I, Joseph J (2021) Andrographolide as a potential inhibitor of SARS-CoV- 2 main protease: an in-silico approach. J Biomol Struct Dyn 29:3092–3098
Kodchakorn K, Poovorawan Y, Suwannakarn K, Kongtawelert P (2020) Molecular modelling investigation for drugs and nutraceuticals against protease of SARS-CoV- 2. J Mol Graph Model 101:107717
Lakshmi SA, Shafreen RMB, Priya A, Shunmugiah KP (2020) Ethnomedicines of Indian origin for combating COVID-19 infection by hampering the viral replication: using structure-based drug discovery approach. J Biomol Struct Dyn 39:4594–4609
Maurya VK, Kumar S, Prasad AK, Bhatt MLB, Saxena SK (2020) Structure-based drug designing for potential antiviral activity of selected natural products from ayurveda against SARS-CoV- 2 spike glycoprotein and its cellular receptor. Virusdisease 31:179–193
Murugan NA, Pandian CJ, Jeyakanthan J (2020) Computational investigation on Andrographis paniculata phytochemicals to evaluate their potency against SARS-CoV- 2 in comparison to known antiviral compounds in drug trials. J Biomol Struct Dyn 39:4415–4426
Rathinavel T, Thangaswamy S, Ammashi S, Kumarasamy S (2020) Virtual screening of COVID-19 drug from three Indian traditional medicinal plants through in silico approach. Res J Biotechnol 15:124–140
Sharma A, Vora J, Patel D, Sinha S, Jha PC, Shrivastava N (2020) Identification of natural inhibitors against prime targets of SARS-CoV- 2 using molecular docking, molecular dynamics simulation and MM-PBSA approaches. J Biomol Struct Dyn:1–16
Sukardiman, Ervina M, Fadhil Pratama MR, Poerwono H, Siswodihardjo S (2020) The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. a Ness). J Adv Pharm Technol Res 11:157–162
Wang T, Liu B, Zhang W, Wilson B, Hong J-S (2004) Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. J Pharmacol Exp Ther 308:975–983
Li J, Luo L, Wang X, Liao B, Li G (2009) Inhibition of NF-kappaB expression and allergen-induced airway inflammation in a mouse allergic asthma model by andrographolide. Cell Mol Immunol 6:381–385
Naik SR, Hule A (2009) Evaluation of immunomodulatory activity of an extract of andrographolides from Andographis paniculata. Planta Med 75:785–791
Suresh V, Deepika G, Bantal V, Beedu SR, Rupula K (2018) Evaluation of anti-inflammatory and anti-nociceptive potentials of andrographolide and forskolin: In vivo studies. J biol act prod nat 8:326–334
Li Y, He S, Tang J, Ding N, Chu X, Cheng L, Wu J (2017) Andrographolide inhibits inflammatory cytokines secretion in LPS-stimulated RAW264. 7 cells through suppression of NF-κB/MAPK signaling pathway. Evid Based Complement Altern Med 8248142
Wang W, Wang J, Dong S-F, Liu C-H, Italiani P, Sun S-H, Xu J, Boraschi D, Ma S-P, Qu D (2010) Immunomodulatory activity of andrographolide on macrophage activation and specific antibody response. Acta Pharmacol Sin 31:191–201
Enayatkhani M, Hasaniazad M, Faezi S, Gouklani H, Davoodian P, Ahmadi N, Einakian MA, Karmostaji A, Ahmadi K (2021) Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in-silico study. J Biomol Struct Dyn 39:2857–2872
Dallakyan S, Olson AJ (2015) Small-molecule library screening by docking with PyRx. Methods Mol Biol 1263:243–250
Adeniji SE, Arthur DE, Oluwaseye A (2020) Computational modeling of 4-Phenoxynicotinamide and 4-Phenoxypyrimidine-5-carboxamide derivatives as potent anti-diabetic agent against TGR5 receptor. J King Saud Univ Sci 32:102–115
Uttekar MM, Das T, Pawar RS, Bhandari B, Menon V, Nutan GSK, Bhat SV (2012) Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding. Eur J Med Chem 56:368–374
Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R (2003) Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300:1763–1767
Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, Schulz L, Widera M, Mehdipour AR, Tascher G, Geurink PP, Wilhelm A, van der Heden VAN, Noort GJ, Ovaa H, Müller S, Knobeloch K-P, Rajalingam K, Schulman BA, Cinatl J, Hummer G, Ciesek S, Dikic I (2020) Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587:657–662
Lipinski CA (2004) Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 1:337–341
Lindner HA, Fotouhi-Ardakani N, Lytvyn V, Lachance P, Sulea T, Ménard R (2005) The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 79:15199–15208
Li D, Luan J, Zhang L (2021) Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors. Biochem Biophys Res Commun 538:72–79
Kirchdoerfer RN, Ward AB (2019) Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 10:2342
Elfiky AA (2020) Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci 253:117592
Vijayan R, Gourinath S (2021) Structure-based inhibitor screening of natural products against NSP15 of SARS-CoV-2 revealed thymopentin and oleuropein as potent inhibitors. J Proteins Proteom 12:1–10
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, Graham BS, McLellan JS (2020) Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367:1260–1263